RT Journal Article
SR Electronic
T1 Double COVID-19 Confirmed Case Fatality Rate in Countries with High Elderly Female Vitamin D Deficiency Prevalence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.13.20130484
DO 10.1101/2020.06.13.20130484
A1 Bäcker, Alex
A1 Mageswaran, Myron
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130484.abstract
AB A number of clues point to a possible role of vitamin D in fighting COVID-19: a reduction in case growth speed with solar zenith angle, higher fatality rate in black people, lower fatality rate in populations that spend more time outdoors. Yet a direct demonstration that vitamin D deficiency is associated with COVID-19 fatalities has remained elusive. We show here in a comparison of 32 countries that countries with high prevalence of vitamin D deficiency among elderly females show a confirmed case fatality rate twice as high as those with low prevalence. We then show that this effect cannot be explained by differences in life expectancy between countries. A mechanistic role for vitamin D in the severity of COVID-19 is proposed.One Sentence Summary Vitamin D deficiency among elderly females is associated with countrywide COVID-19 confirmed case fatality rates up to twice as high as those of countries with low vitamin D deficiency prevalence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding other than software support from Mathworks, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None relevant. No human subjects were used in this study; only aggregated country-level data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available. https://docs.google.com/spreadsheets/d/19VyevkN4hp_oNgXJkwMpav7-9Xc7yDfjqt19M3f_SiU/edit?usp=sharing